ライフサイエンスコーパス: monophosphoryl

1 The macaques were boosted with SIV gp120 in monophosphoryl A-stable emulsion adjuvant at 24 and 36 w

2 responsible for the formation of decaprenyl-monophosphoryl-beta-D-arabinose (DPA) in the genome of M

3 ng the sugar donor beta-d-arabinofuranosyl-1-monophosphoryl-decaprenol (DPA) and a newly synthesized

4 zing the sugar donor beta-D-mannopyranosyl-1-monophosphoryl-decaprenol together with the neoglycolipi

5 t transfer the 2'-azido-2'-deoxyadenosine 5'-monophosphoryl group (2'-Az-dAMP) from the analogous 5'-

6 erases catalyze the transfer of a nucleoside monophosphoryl group from a nucleotide to a hydroxyl gro

7 CSK4 (TLR1/2 ligand), FSL-1 (TLR2/6 ligand), monophosphoryl lipid (MPL)-A, lipopolysaccharide (LPS, b

8 AS04 comprising alum (Al) and 3-deactylated monophosphoryl lipid A (3-dMPL) afforded HSV-seronegativ

9 zation with rPhpA-79 protein adjuvanted with monophosphoryl lipid A (for subcutaneous immunization) o

10 We previously showed that monophosphoryl lipid A (MLA) activates TLR4 in dendritic

11 l fatty acid chain length in the 3-O-desacyl monophosphoryl lipid A (MLA) series is shown to be a cri

12 e used to achieve early preconditioning, and Monophosphoryl lipid A (MLA) was used to induce late pre

13 Monophosphoryl lipid A (MLA), a nontoxic analogue of end

14 s based on the structure of lipid A, such as monophosphoryl lipid A (MLA), have proven to be safe and

15 phosphoryl lipid A (dLPA) but only weakly to monophosphoryl lipid A (mLPA).

16 ss pollen allergoids containing the adjuvant monophosphoryl lipid A (MPL((R)) ); 51 control patients

17 th either a low or high dose of 3-deacylated monophosphoryl lipid A (MPL) and administered with alum

18 ps were boosted with FI-HSV2 formulated with monophosphoryl lipid A (MPL) and alum adjuvants.

19 in CHO cells and given intramuscularly with monophosphoryl lipid A (MPL) and alum, or gC2 and gD2 we

20 e particle (VLP) vaccine with 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and alum.

21 from norovirus GI.1 genotype adjuvanted with monophosphoryl lipid A (MPL) and the mucoadherent chitos

22 The effectiveness of monophosphoryl lipid A (MPL) as a mucosal adjuvant was i

23 ory molecule SA-4-1BBL with the TLR4 agonist monophosphoryl lipid A (MPL) as a novel vaccine adjuvant

24 uble truncated gD protein (gD2t) in alum and monophosphoryl lipid A (MPL) elicited high neutralizing

25 Monophosphoryl lipid A (MPL) from Salmonella typhimurium

26 Monophosphoryl lipid A (MPL) is a nontoxic derivative of

27 Monophosphoryl lipid A (MPL) is a nontoxic derivative of

28 Monophosphoryl lipid A (MPL) is an LPS-derived Toll-like

29 nsisting of glycoprotein D (gD2) in alum and monophosphoryl lipid A (MPL) reduced genital herpes dise

30 capsulation of RTS,S in liposomes containing monophosphoryl lipid A (MPL) resulted in a dose-dependen

31 essed whether prophylactic administration of monophosphoryl lipid A (MPL), a nontoxic derivative of l

32 tranasal (i.n.) immunization of rHagB and if monophosphoryl lipid A (MPL), a nontoxic derivative of t

33 e investigated whether nHgbAI dispensed with monophosphoryl lipid A (MPL), an adjuvant approved for u

34 ) vaccine candidate adjuvanted with alum and monophosphoryl lipid A (MPL), blockade Ab titers peaked

35 the nonspecific biological response modifier monophosphoryl lipid A (MPL), given in vivo or incubated

36 Addition of adjuvants, such as monophosphoryl lipid A (MPL), might allow for efficaciou

37 -gp160, formulated with liposomes containing monophosphoryl lipid A (MPL), MPL-AF, proteosomes, emuls

38 ng its superiority to vaccines adjuvanted by monophosphoryl lipid A (MPL)-alum.

39 y in the presence of an additional adjuvant, monophosphoryl lipid A (MPL).

40 Monophosphoryl lipid A (MPLA) is a low-toxicity derivati

41 Monophosphoryl lipid A (MPLA) is a Toll-like receptor 4

42 nal adjuvant alum or the molecular adjuvants monophosphoryl lipid A (MPLA) or alpha-galactosylceramid

43 th ovalbumin (OVA) and a molecular adjuvant, monophosphoryl lipid A (MPLA) promoted BMDC maturation a

44 inked to keyhole limpet hemocyanin (KLH) and monophosphoryl lipid A (MPLA) to form novel therapeutic

45 Monophosphoryl lipid A (MPLA), a less toxic derivative o

46 Monophosphoryl lipid A (MPLA), a low toxicity derivative

47 Monophosphoryl lipid A (MPLA), a nontoxic TLR4 ligand de

48 Immunization with these particles and monophosphoryl lipid A (MPLA), a US Food and Drug Admini

49 Surprisingly, monophosphoryl lipid A (MPLA), another TLR4 ligand, enha

50 Priming of mice with LPS, monophosphoryl lipid A (MPLA), or poly(I:C) significantl

51 cts of VTX-294 and R-848 in combination with monophosphoryl lipid A (MPLA; TLR4) were also assessed.

52 ificant levels of Ab reactivity in the NS1 + monophosphoryl lipid A + AddaVax group.

53 bined with aluminum and magnesium hydroxide, monophosphoryl lipid A + AddaVax, or Sigma adjuvant syst

54 we evaluated the effects of adjuvant AS01B (monophosphoryl lipid A [MPL] and QS21), CpG 10105, and t

55 ied in a dimethyldioctadecylammonium bromide-monophosphoryl lipid A adjuvant and tested for the abili

56 combinant HSV-2 glycoprotein D (gD2) in alum-monophosphoryl lipid A adjuvant only in HSV women serone

57 e in both flight and ground cohorts received monophosphoryl lipid A alone without additional OVA stim

58 ice with PppA protein and either a synthetic monophosphoryl lipid A analog, RC529AF, or a cholera tox

59 5/50 and 50/50 formulations) adjuvanted with monophosphoryl lipid A and Al(OH)3 We present safety and

60 led to incorporate the amphipathic adjuvants monophosphoryl lipid A and cholesterol-modified CpG olig

61 ose promoted by the well-studied TLR agonist monophosphoryl lipid A and comparable to a much larger d

62 ized with HCV-LP, HCV-LP and adjuvant AS01B (monophosphoryl lipid A and QS21), or HCV-LP and the comb

63 -in-water emulsion plus the immunostimulants monophosphoryl lipid A and the saponin derivative QS21 (

64 orates two immune stimulants, 3-O-desacyl-4'-monophosphoryl lipid A and the saponin QS-21.

65 d vaccine adjuvant containing 3-O-desacyl-4'-monophosphoryl lipid A and the saponin QS-21.

66 nd B5R proteins in an adjuvant consisting of monophosphoryl lipid A and trehalose dicorynomycolate or

67 ke particle (VLP) vaccine (with chitosan and monophosphoryl lipid A as adjuvants) to prevent acute vi

68 model of chancroid, using either Freund's or monophosphoryl lipid A as adjuvants.

69 s toxoid and mixed with liposomes containing monophosphoryl lipid A as an adjuvant.

70 in D from HSV-2 with alum and 3-O-deacylated monophosphoryl lipid A as an adjuvant; control subjects

71 In this way, the immunostimulant activity of monophosphoryl lipid A can significantly improve the imm

72 A semisynthetic strategy to obtain monophosphoryl lipid A derivatives equipped with clickab

73 dministration of ADX40-Id with 3-O-deacyl-4'-monophosphoryl lipid A further significantly enhanced va

74 ection induced by Leish-111f formulated with monophosphoryl lipid A in a stable emulsion (Leish-111f+

75 subunit vaccine with alum and 3-O-deacylated-monophosphoryl lipid A in subjects whose regular sexual

76 combination with lipopolysaccharide (LPS) or monophosphoryl lipid A led to strongly synergistic produ

77 stable emulsion (SE) with the TLR4 agonists monophosphoryl lipid A or glucopyranosyl lipid A (GLA) h

78 and rabbits was enhanced by formulation with monophosphoryl lipid A plus trehalose dimycolate.

79 e conjugate was enhanced by formulation with monophosphoryl lipid A plus trehalose dimycolate.

80 terol-rich liposomes containing the adjuvant monophosphoryl lipid A results in the production of anti

81 reas the TLR4 ligands lipopolysaccharide and monophosphoryl lipid A substantially augmented the magni

82 is, which were eliminated by the addition of monophosphoryl lipid A to the formulation.

83 Stimulation with the TLR-4 ligand monophosphoryl lipid A together with IFN-gamma (alt-2 DC

84 Monophosphoryl lipid A was prepared from the lipopolysac

85 -MPL (aluminum hydroxide plus 3-O-desacyl-4'-monophosphoryl lipid A) induced robust L2 antibodies (EL

86 nosinic-polycytidylic acid [poly-IC]), TLR4 (monophosphoryl lipid A), TLR7/8 (3M-012), TLR9 (CpG), or

87 For example, monophosphoryl lipid A, a family of endotoxic TLR4 agoni

88 The addition of monophosphoryl lipid A, a minimally toxic derivative of

89 in approved products is AS04, which combines monophosphoryl lipid A, a TLR-4 agonist, with alum.

90 accine candidate, in conjunction with either monophosphoryl lipid A, a TLR4 agonist, or CpG, a TLR9 a

91 d with alum and the detoxified LPS adjuvant, monophosphoryl lipid A, provided some protection to the

92 han the wild-type allergens and a registered monophosphoryl lipid A-adjuvanted vaccine based on natur

93 A1 was combined with commercially available monophosphoryl lipid A-based adjuvant, and after immuniz

94 protein formulated with either Alhydrogel or monophosphoryl lipid A-containing adjuvants resulted in

95 Only mice treated with L110f plus monophosphoryl lipid A-CpG were able to induce a strong

96 erule-derived proline-rich antigen (rPRA) in monophosphoryl lipid A-oil emulsion adjuvant or a DNA va

97 The endogenous production of calcitriol by monophosphoryl lipid A-stimulated DCs appeared to be Tol

98 A monophosphoryl lipid A-Thomson-Friedenreich (TF) antigen

99 co-stimulated with the TLR4-agonist adjuvant monophosphoryl lipid A.

100 OVA) 323-339 plus the inflammatory adjuvant, monophosphoryl lipid A.

101 by using the combined adjuvant of alum plus monophosphoryl lipid A.

102 adjuvant, Freund's incomplete adjuvant, and monophosphoryl-lipid A/trehalose dicorynomycolate adjuva